Funding profile · Genomics software

Haplotype Labs

One Form D, filed in April 2024, fully subscribed at $1.1 million from five investors. Nothing has been filed since. The gap between that number and the $1.6 million the aggregators report is almost exactly the size of a Y Combinator check.

$1.10MOffered and sold in full, Form D filed Apr 16, 2024
$220KAverage per investor across five investors
$1.6MTotal raised to date, per PitchBook and CB Insights
$0Federal grant dollars on record, NIH and NSF

Data as of September 23, 2026. Company-reported and vendor-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Winter 2024 Y Combinator batch Standard deal, $500,000 Y Combinator YC published terms
Mar 29, 2024 First sale in the Reg D offering Part of $1,100,000 Not named in the filing Form D
Apr 16, 2024 Form D filed, equity $1,100,000 offered, $1,100,000 sold 5 investors, minimum $50,000 Form D
Apr 15, 2024 Seed, as dated by PitchBook $1.1M 645 Ventures, Brainstorm Ventures, Soma Capital, Y Combinator Vendor data
Through Sep 2026 Total raised to date $1.6M Not itemized Vendor data
2024 to 2026 Federal grants None No NIH or NSF award found Not found

What the filings show

Haplotype Labs, Inc. · Form D · filed Apr 16, 2024

First sale
Mar 29, 2024
Offered
$1,100,000 equity
Sold
$1,100,000 · $0 remaining
Investors
5 · average $220,000 · minimum accepted $50,000
Exemptions
Rule 504(b)(1) and Rule 506(b), both checked
Related persons
Michael Polcari, executive officer. No directors listed.
Issuer detail
Delaware corporation, incorporated 2024. Industry group: Other Technology. Revenue range: decline to disclose. Sales commissions and finders fees: $0. Offering not intended to last more than one year.
Filing
SEC EDGAR, CIK 0002017857

Reading the filings

  1. Five checks of institutional size.$1,100,000 divided by five investors is $220,000 each, against a stated minimum of $50,000. That is a fund sized ticket, not an angel list, and it matches the four venture names PitchBook attaches to the round.
  2. The round closed at exactly what was offered.Offered $1,100,000, sold $1,100,000, remaining $0, reported on a new notice rather than an amendment. A company that files after the offering is complete has already decided how much it wants.
  3. The missing $500,000 is the size of a YC deal.PitchBook and CB Insights both put total raised at $1.6 million. Subtract the $1.1 million on the Form D and $500,000 is left. Y Combinator publishes its standard deal as $500,000, made as a $125,000 post-money SAFE for 7% plus a $375,000 uncapped MFN SAFE. Dealroom separately logs a $125k seed entry for the company. SAFEs are commonly sold under Section 4(a)(2), which requires no Form D, so the arithmetic is consistent even though only one notice exists.
  4. The notice claims two federal exemptions.Both Rule 504(b)(1) and Rule 506(b) are checked on the same form. The filing does not say why both, and the two rules carry different offering ceilings and different state law consequences.
  5. No board has been disclosed.Item 3 names one related person, Michael Polcari, as executive officer. No director is listed, on a round with four named venture investors. Either no board seat was taken or none was reported.
  6. Nothing has been filed in 29 months.First sale was March 29, 2024. There is no amendment and no second Form D through September 23, 2026, and no aggregator records a round after April 2024. Money raised under Section 4(a)(2) leaves no Form D, so silence is not proof that nothing moved, but it is also not evidence that anything did.
  7. A genomics company filed as Other Technology.The issuer skipped the Health Care, Biotechnology and Pharmaceuticals boxes and selected Other Technology, and declined to disclose revenue. The principal place of business on the filing is a residential street address in Orinda, California.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k), de novo or PMA names Haplotype Labs. The company sells software to laboratories and does not claim a CLIA certificate of its own. Not found
Clinical evidence No registered trial, no PubMed record, no NIH or NSF award. Not found
Customers None named. Buyer categories only: genetic testing labs, concierge practices, clinical trials, consumer brands, payers and providers. Not found
Headcount One employee, reported by Y Combinator in 2024 and still reported as one in 2026. Vendor data
Intellectual property Founder named on multiple 23andMe patent filings, including a polygenic scoring platform application published Aug 21, 2025. No patent assigned to Haplotype Labs found. Public record
Market timing Polygenic risk recognized as a risk enhancing factor in the 2026 ACC/AHA cardiovascular guidelines, per a competitor announcement in March 2026. Competitor release
Visibility Founder listed in the AI and data sciences showcase at PMWC 2026 Silicon Valley, March 4 to 6, 2026. Conference

What to watch

  • A second Form D. It would be due within 15 days of a first sale in a new offering.
  • An amended notice or a new filing that names directors, which would show whether an investor took a board seat.
  • Any named customer or disclosed revenue, both absent from every record reviewed.
  • Whether headcount moves past one, the only operating number any source reports.

The Haplotype Labs story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Spiral Genetics: Shared investor: Form D. Healthcare Venture Capital. A Seattle company that spent a decade trying to make cheap short read sequencing see the big mutations everyone else was missing
  • Legion Health: Shared investor: Soma Capital. An AI native psychiatry clinic holding the second agreement Utah has ever signed to let software authorize a prescription renewal
  • Biodock: Shared investor: Soma Capital. A cloud platform that lets a biologist train an image-analysis model without writing code
  • Gradia Health: Shared investor: Soma Capital. A software layer that lets brick and mortar clinics run virtual care teams, dietitians and nurses, for chronic condition patients between visits

Sources

  1. Public recordForm D, Haplotype Labs, Inc., CIK 0002017857SEC EDGAR · Apr 16, 2024
  2. Public recordUS patent application 20250266129 and patents by inventor Michael PolcariUSPTO, via Justia · accessed Sep 23, 2026
  3. IndependentHaplotype Labs company profile, valuation, funding and investorsPitchBook · accessed Sep 23, 2026
  4. IndependentHaplotype Labs company profile, total raisedCB Insights · accessed Sep 23, 2026
  5. IndependentHaplotype Labs company information, funding and investorsDealroom · accessed Sep 23, 2026
  6. IndependentHaplotype Labs company and team size profileLatka · accessed Sep 23, 2026
  7. CompanyThe Y Combinator Standard DealY Combinator · accessed Sep 23, 2026
  8. CompanyHaplotype Labs launch post, company profile and job listingY Combinator · Winter 2024 batch
  9. CompanyMike Polcari speaker profile and talk abstractPMWC 2026 Silicon Valley
  10. PartnerPolygenic risk score recognized in the 2026 ACC/AHA guidelinesAllelica via PR Newswire · Mar 16, 2026

Compiled from SEC and other public records and published reports as of September 23, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Offerings made under Section 4(a)(2) require no Form D. Healthcare Venture Capital Fund holds no position in Haplotype Labs. This page is not an offer to sell or a recommendation to buy any security.